Vera Therapeutics, Inc.
veratx.comWhat Do They Do?
Develops treatments for serious immune diseases, including atacicept for patients with IgA kidney disease and drug candidates for other autoimmune kidney diseases and BK virus infection.
10-K for FY2025, filed Feb 26, 2026We are a late clinical-stage biotechnology company focused on developing and commercializing transformative treatments for patients with…View ↗
We believe that atacicept has pipeline-in-a-molecule potential, with expected application in multiple diseases. Based on data from the…View ↗
We also hold worldwide, exclusive development and commercial rights to MAU868, a potentially first-in-class monoclonal antibody to treat…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Feb 26, 2026
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 10, 2026
−$109.5MView ↗
- ▲ +43% (Loss)
- vs −$76.5M in Q2 FY2025
-
Aug 10, 2026
TRUTAKNA receives accelerated approval and U.S. launch begins
FDA approved TRUTAKNA for adults with primary IgAN at risk of progression; the U.S. commercial launch is underway.
Sources
8-K, filed Aug 10, 2026
TRUTAKNA™ granted accelerated approval by U.S. Food and Drug Administration (FDA) in adult patients with primary IgA nephropathy (IgAN) at…View ↗
Development priorities
The older report planned a lupus nephritis trial and delayed resources for it and the BK-virus program; the latest report focuses on completing atacicept’s IgAN development while evaluating further development of the BK-virus program.
10-K for FY2022, filed Mar 28, 2023 10-K for FY2025, filed Feb 26, 2026In January 2023, we announced our plan to prioritize and focus our current resources on the advancement of atacicept in IgAN into a pivotal…View ↗
Who Do They Compete With?
Competes with Asahi Kasei, Otsuka Pharmaceuticals, Novartis, Travere Therapeutics, Roche, Ionis, Vertex, AstraZeneca, Biogen, Takeda, Arrowhead Pharmaceuticals, NovelMed, Eladon Pharmaceuticals, Memo Therapeutics, and Aurinia Pharmaceuticals
10-K for FY2025, filed Feb 26, 2026Among emerging therapies, we consider our most direct competitors with respect to atacicept in IgAN to be approved products: the…View ↗
Loading...
